BACKGROUND: Although MYH9 is strongly associated with biopsy-proven idiopathic and HIV-associated focal segmental glomerulosclerosis (FSGS) and clinically diagnosed 'hypertension-associated' end-stage renal disease (ESRD) in African Americans, its role in type 2 diabetes mellitus (T2DM)-associated ESRD is unclear. METHODS: To assess whether MYH9 was associated with T2DM-ESRD, 751 African Americans with T2DM-ESRD, 227 with T2DM lacking nephropathy and 925 non-diabetic non-nephropathy controls were genotyped for 14 MYH9 SNPs. Association analyses used SNPGWA and Dandelion. RESULTS: Comparing T2DM-ESRD cases with non-diabetic controls, single SNP associations were detected with 8 of 14 SNPs, gender- and admixture-adjusted P-values 0.047-0.005 [recessive model, odds ratio (OR) range 1.30-1.55]. The previously associated MYH9 E1 and L1 haplotypes were associated with T2DM-ESRD (E1: OR 1.27, 95% CI 1.04-1.56, P = 0.021 recessive and L1: OR 1.43, 95% CI 1.09-1.87, P = 0.009 dominant). Contrasting the 751 T2DM-ESRD cases with 227 T2DM non-nephropathy controls revealed that E1 haplotype SNPs rs4821480, rs2032487 and rs4821481 were associated with kidney failure (OR 1.38-1.40 recessive, all P < 0.048). Among E1 and L1 risk homozygotes, respectively, mean (SD) diabetes duration prior to renal replacement therapy was 16.6 (9.7) and 16.4 (10.0) years, and 65% had diabetic retinopathy. CONCLUSIONS: Genetic dissection of T2DM-associated ESRD reveals that MYH9 underlies a portion of this clinically diagnosed disorder in African Americans. It is likely that a subset of African Americans with T2DM and coincident nephropathy have primary MYH9-related kidney disease (e.g. FSGS or global glomerulosclerosis), although renal biopsy studies need to be performed.
BACKGROUND: Although MYH9 is strongly associated with biopsy-proven idiopathic and HIV-associated focal segmental glomerulosclerosis (FSGS) and clinically diagnosed 'hypertension-associated' end-stage renal disease (ESRD) in African Americans, its role in type 2 diabetes mellitus (T2DM)-associated ESRD is unclear. METHODS: To assess whether MYH9 was associated with T2DM-ESRD, 751 African Americans with T2DM-ESRD, 227 with T2DM lacking nephropathy and 925 non-diabetic non-nephropathy controls were genotyped for 14 MYH9 SNPs. Association analyses used SNPGWA and Dandelion. RESULTS: Comparing T2DM-ESRD cases with non-diabetic controls, single SNP associations were detected with 8 of 14 SNPs, gender- and admixture-adjusted P-values 0.047-0.005 [recessive model, odds ratio (OR) range 1.30-1.55]. The previously associated MYH9 E1 and L1 haplotypes were associated with T2DM-ESRD (E1: OR 1.27, 95% CI 1.04-1.56, P = 0.021 recessive and L1: OR 1.43, 95% CI 1.09-1.87, P = 0.009 dominant). Contrasting the 751 T2DM-ESRD cases with 227 T2DM non-nephropathy controls revealed that E1 haplotype SNPs rs4821480, rs2032487 and rs4821481 were associated with kidney failure (OR 1.38-1.40 recessive, all P < 0.048). Among E1 and L1 risk homozygotes, respectively, mean (SD) diabetes duration prior to renal replacement therapy was 16.6 (9.7) and 16.4 (10.0) years, and 65% had diabetic retinopathy. CONCLUSIONS: Genetic dissection of T2DM-associated ESRD reveals that MYH9 underlies a portion of this clinically diagnosed disorder in African Americans. It is likely that a subset of African Americans with T2DM and coincident nephropathy have primary MYH9-related kidney disease (e.g. FSGS or global glomerulosclerosis), although renal biopsy studies need to be performed.
Authors: William C Knowler; Josef Coresh; Robert C Elston; Barry I Freedman; Sudha K Iyengar; Paul L Kimmel; Jane M Olson; Rosemarie Plaetke; John R Sedor; Michael F Seldin Journal: J Diabetes Complications Date: 2005 Jan-Feb Impact factor: 2.852
Authors: Barry I Freedman; Pamela J Hicks; Meredith A Bostrom; Mary E Cunningham; Yongmei Liu; Jasmin Divers; Jeffrey B Kopp; Cheryl A Winkler; George W Nelson; Carl D Langefeld; Donald W Bowden Journal: Kidney Int Date: 2009-01-28 Impact factor: 10.612
Authors: M Seri; R Cusano; S Gangarossa; G Caridi; D Bordo; C Lo Nigro; G M Ghiggeri; R Ravazzolo; M Savino; M Del Vecchio; M d'Apolito; A Iolascon; L L Zelante; A Savoia; C L Balduini; P Noris; U Magrini; S Belletti; K E Heath; M Babcock; M J Glucksman; E Aliprandis; N Bizzaro; R J Desnick; J A Martignetti Journal: Nat Genet Date: 2000-09 Impact factor: 38.330
Authors: Marco Seri; Maria Savino; Domenico Bordo; Roberto Cusano; Bianca Rocca; Ilaria Meloni; Filomena Di Bari; Pasi A Koivisto; Martino Bolognesi; Gian Marco Ghiggeri; Raffaele Landolfi; Carlo L Balduini; Leopoldo Zelante; Roberto Ravazzolo; Alessandra Renieri; Anna Savoia Journal: Hum Genet Date: 2001-12-14 Impact factor: 4.132
Authors: Meredith A Bostrom; Lingyi Lu; Jeff Chou; Pamela J Hicks; Jianzhao Xu; Carl D Langefeld; Donald W Bowden; Barry I Freedman Journal: Hum Genet Date: 2010-06-08 Impact factor: 4.132
Authors: Barry I Freedman; Carl D Langefeld; Mariana Murea; Lijun Ma; James D Otvos; Jolyn Turner; Peter A Antinozzi; Jasmin Divers; Pamela J Hicks; Donald W Bowden; Michael V Rocco; John S Parks Journal: Nephrol Dial Transplant Date: 2011-09-19 Impact factor: 5.992
Authors: David J Friedman; Julia Kozlitina; Giulio Genovese; Prachi Jog; Martin R Pollak Journal: J Am Soc Nephrol Date: 2011-10-13 Impact factor: 10.121
Authors: Isai Gopalakrishnan; Samy S Iskandar; Pirouz Daeihagh; Jasmin Divers; Carl D Langefeld; Donald W Bowden; Pamela J Hicks; Michael V Rocco; Barry I Freedman Journal: Hum Pathol Date: 2010-11-13 Impact factor: 3.466
Authors: Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak Journal: Science Date: 2010-07-15 Impact factor: 47.728
Authors: J M Hester; M R Wing; J Li; N D Palmer; J Xu; P J Hicks; B H Roh; J M Norris; L E Wagenknecht; C D Langefeld; B I Freedman; D W Bowden; M C Y Ng Journal: Int J Obes (Lond) Date: 2011-07-12 Impact factor: 5.095